- Home
- WXM vs NERV Comparison
WXM vs NERV Comparison
Compare WXM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WXM
- NERV
- Stock Information
- Founded
- WXM 2009
- NERV 2007
- Country
- WXM China
- NERV United States
- Employees
- WXM N/A
- NERV N/A
- Industry
- WXM
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- WXM
- NERV Health Care
- Exchange
- WXM NYSE
- NERV Nasdaq
- Market Cap
- WXM 15.2M
- NERV 12.6M
- IPO Year
- WXM 2025
- NERV 2014
- Fundamental
- Price
- WXM $2.35
- NERV $1.77
- Analyst Decision
- WXM
- NERV Hold
- Analyst Count
- WXM 0
- NERV 1
- Target Price
- WXM N/A
- NERV $5.00
- AVG Volume (30 Days)
- WXM 59.0K
- NERV 13.4K
- Earning Date
- WXM 01-01-0001
- NERV 08-05-2025
- Dividend Yield
- WXM N/A
- NERV N/A
- EPS Growth
- WXM 67.61
- NERV N/A
- EPS
- WXM 0.18
- NERV 0.83
- Revenue
- WXM $15,524,259.00
- NERV N/A
- Revenue This Year
- WXM N/A
- NERV N/A
- Revenue Next Year
- WXM N/A
- NERV N/A
- P/E Ratio
- WXM $13.37
- NERV $2.17
- Revenue Growth
- WXM 10.86
- NERV N/A
- 52 Week Low
- WXM $1.52
- NERV $1.15
- 52 Week High
- WXM $7.99
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- WXM N/A
- NERV 55.49
- Support Level
- WXM N/A
- NERV $1.62
- Resistance Level
- WXM N/A
- NERV $1.87
- Average True Range (ATR)
- WXM 0.00
- NERV 0.11
- MACD
- WXM 0.00
- NERV 0.00
- Stochastic Oscillator
- WXM 0.00
- NERV 55.93
About WXM WF INTERNATIONAL LIMITED
WF International Ltd is engaged in the provision of supply, installation, fitting-out and maintenance services for HVAC system and floor heating systems. It provides the supply, installation and fitting-out services for HVAC systems for large-scaled commercial projects consisting of offices, hotels, manufactures, airports and hospitals, such as the International Finance Square HVAC projects across China, Chengdu Vanke Charm City, Chengdu Raffles Plaza, Chengdu Yinshi Plaza, Chengdu Metro No. Ten Line, and Panzhihua Jinhai Hotel.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.